Sirana to Collaborate with Pfizer to Investigate Novel Treatment for Rare Bone Disease

German biotech Sirana Pharma entered a collaborative research agreement with Pfizer to investigate the potential identification and validation of a novel treatment concept for a rare bone disease.

Photo: Michael Kring, CEO of Sirana Pharma

The collaboration will utilize Sirana’s proprietary microRNA-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.

“Combining Sirana’s novel miRNA-targeting approach, and the long-standing experience in musculoskeletal disorders and disease mechanisms of its founders, with the expertise and competencies of Pfizer will allow Sirana to expeditiously evaluate its drug candidates for the treatment of this rare disease and to identify potential candidates for further development,” said Michael Kring, CEO of Sirana Pharma.

Sirana has discovered a novel, innovative mode of action for the treatment of several musculoskeletal disorders and patented a microRNA-targeting approach, which targets substantial regenerative recovery of diseased skeletal muscle and bone tissue. Initially, Sirana is focusing on the development of first-in-class molecules to treat sarcopenia, or age related muscle weakness, and osteogenesis imperfecta, a rare genetic brittle bone disease.

Author: Rare Daily Staff